Journal of Hepatology

Article	Citations
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update	1998
Baveno VII – Renewing consensus in portal hypertension	1203
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update	885
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma	733
Global burden of primary liver cancer in 2020 and predictions to 2040	729
EASL recommendations on treatment of hepatitis C: Final update of the series☆	711
A multisociety Delphi consensus statement on new fatty liver disease nomenclature	683
Global burden of liver disease: 2023 update	417
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study	371
COVID-19 and the liver	371
Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis	319
Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma	313
COVID-19: Discovery, diagnostics and drug development	301
Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients	283
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials	274
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma	272
Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States	268
High rates of 30-day mortality in patients with cirrhosis and COVID-19	266
Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients	258
Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy	252
Systemic treatment of hepatocellular carcinoma: An EASL position paper	244
The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis	234
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores	223
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits	211
Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis	200

Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis	196
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy	194
Impact of COVID-19 on global HCV elimination efforts	193
Epidemiology and risk-stratification of NAFLD-associated HCC	189
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis	188
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis	185
Sarcopenia and frailty in decompensated cirrhosis	183
Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis	183
Single-cell genomics and spatial transcriptomics: Discovery of novel cell states and cellular interactions in liver physiology and disease biology	182
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy	177
Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction	173
EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients	172
EASL Clinical Practice Guidelines on the management of hepatic encephalopathy	172
Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis	171
Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma	169
Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?	163
A new perspective on NAFLD: Focusing on lipid droplets	162
PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis	158
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry	156
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort	151
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options	150
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score	149
EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis	149
Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease	147
Reply to: correspondence regarding “A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement”	145
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis	140
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?	137
Mitochondrial alterations in fatty liver diseases	137
Changing epidemiology, global trends and implications for outcomes of NAFLD	136
Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription	135
EASL Clinical Practice Guidelines on sclerosing cholangitis	134
The microbiota in cirrhosis and its role in hepatic decompensation	133
Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis	133
Peptide SMIM30 promotes HCC development by inducing SRC/YES1 membrane anchoring and MAPK pathway activation	130
Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease	128
Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease	128
Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases	128
Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial	126
Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension	120
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease	118
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma	118
Current knowledge and management of portal vein thrombosis in cirrhosis	118
COMMD10 inhibits HIF1α/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma	117
Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease	117
Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS	117
Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view	116
Combined hepatocellular-cholangiocarcinoma: An update	114
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS)	114
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial	112
Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019	111

MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma	111
Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial	108
Impact of non-invasive biomarkers on hepatology practice: Past, present and future	107
Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial	106
Can we use old NAFLD data under the new MASLD definition?	106
Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease	105
The changing context of hepatitis D	104
Association of liver abnormalities with in-hospital mortality in patients with COVID-19	104
HCC surveillance after SVR in patients with F3/F4 fibrosis	104
Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality	104
Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling	103
Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma	100
Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease	99
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?	98
A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes	98
ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis	96
Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis	96
Management of bacterial and fungal infections in cirrhosis: The MDRO challenge	95
Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta	95
99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical	95
MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis	95
Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry	94
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis	94
Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease	94
Combination immunotherapy for hepatocellular carcinoma	94
Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma	94
Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model	93
Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure	93
Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease	92
Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure	92
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease	92
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA	92
Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors	91
Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis	91
Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD	91
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH	90
Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events	90
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study	89
rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis	89
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma	89
Towards a new definition of decompensated cirrhosis	88
SARS-CoV-2 infection in patients with autoimmune hepatitis	87
Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival	86
The fecal mycobiome in non-alcoholic fatty liver disease	86
Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer	86
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs	86
Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons	86
Breakthroughs in therapies for NASH and remaining challenges	85
Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH	84
CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma	84
A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis	84
Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B	83
Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity	82
SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis	82
Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study	81
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group	81
Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity	81
Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx	81
DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer	79
Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections	78
Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study	77
Asian perspective on NAFLD-associated HCC	77
Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy	77
HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease	77
Systemic treatment of HCC in special populations	77
Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis	76
Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention	76
Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study)	76
The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease	76
Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]	75
Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma	75
Another case of autoimmune hepatitis after SARS-CoV-2 vaccination – still casualty?	75
The mRNA COVID-19 vaccine – A rare trigger of autoimmune hepatitis?	75
Hepatokines and adipokines in NASH-related hepatocellular carcinoma	75
Cell therapy for advanced liver diseases: Repair or rebuild	74
Metabolic reprogramming in cholangiocarcinoma	74
EASL Clinical Practice Guidelines on hepatitis delta virus	74
Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease	74
Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma	74
Autoimmune hepatitis following SARS-CoV-2 vaccine: May not be a casuality	73

Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load	73
Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD	73
Hepatic benefits of HCV cure	73
Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications	73
Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores	72
The stigma of alcohol-related liver disease and its impact on healthcare	71
Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990–2019	71
Porto-sinusoidal vascular disorder	70
Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: First report in Europe	70
Acute-on-chronic liver failure: A distinct clinical syndrome	70
Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation	69
Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure	68
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels	68
Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites	68
Autoimmune hepatitis following COVID-19 vaccination: True causality or mere association?	68
PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma	67
Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group	67
Blocking CD47 promotes antitumour immunity through CD103+ dendritic cell–NK cell axis in murine hepatocellular carcinoma model	67
Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis	67
Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma	67
Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis	67
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma	66
EASL Clinical Practice Guidelines on haemochromatosis	66
A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation	66
Liver injury following SARS-CoV-2 vaccination: A multicenter case series	66
Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies	66
Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?	66
Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis	66
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B	66
Current epidemiology of cholangiocarcinoma in Western countries	65
Treatment failure with DAA therapy: Importance of resistance	65
Cigarette smoking and liver diseases	65
Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis	64
A multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation	64
Bile formation and secretion: An update	64
The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs	63
Diagnosis and management of secondary causes of steatohepatitis	63
Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis	62
Bilirubin: The yellow hormone?	62
An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B	62
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma	62
Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis	62
Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target	61
Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants	61
A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA	61
RETRACTED: Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance	60
Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients	60
Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis	60
Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality	60
A global investment framework for the elimination of hepatitis B	60
Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure	60
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study	59
Endoplasmic reticulum-mitochondria miscommunication is an early and causal trigger of hepatic insulin resistance and steatosis	59
Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis	59
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease	58
Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma	58
Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design	58
An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease	58
NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression – The debate continues	58
Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis	58
Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies	57
Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease	57
Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH	56
Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties	56
Chronic hepatitis E: Advancing research and patient care	55
FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2	55
EASL Clinical Practice Guidelines on acute-on-chronic liver failure	55
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD	55
FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease	55
p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma	55
Myeloid Ikaros–SIRT1 signaling axis regulates hepatic inflammation and pyroptosis in ischemia-stressed mouse and human liver	55
FXR agonists for NASH: How are they different and what difference do they make?	55
Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine	54
Personalized surveillance for hepatocellular carcinoma in cirrhosis – using machine learning adapted to HCV status	54
Vitamin B12 and folate decrease inflammation and fibrosis in NASH by preventing syntaxin 17 homocysteinylation	54
Blocking integrin α4β7-mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis	53
Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity	53
Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed	53
Gut-derived systemic inflammation as a driver of depression in chronic liver disease	53
Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology	53
Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death	53
Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR	53
New clinical and pathophysiological perspectives defining the trajectory of cirrhosis	53
Promises of microbiome-based therapies	52
Rational HCC screening approaches for patients with NAFLD	52
Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma	52
Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis	52
STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway	52
Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis	52
Protective mechanisms and current clinical evidence of hypothermic oxygenated machine perfusion (HOPE) in preventing post-transplant cholangiopathy	51
Maternal obesity increases the risk and severity of NAFLD in offspring	51
Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF	51
Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States	51
Clinical utility of the MAFLD definition	51
The multifactorial mechanisms of bacterial infection in decompensated cirrhosis	50